⚠ Public Money Sets the PaceModerate threat

Synektik (SNT) — threat to the moat

Synektik's growth was switched on by a reimbursement decision, and only another one will keep it running at this pace.

Synektik sells to one kind of customer paid by one kind of payer. Public procurement produced 85,5% of group revenue in the year to September 20251. The operations that use its robots are paid for by the NFZ, which spent about 300 million złoty on nearly 11 000 robotic cancer operations in 20242, and only on three cancers3. The company lists the level of public health funding among the main factors affecting its results4.

Polish da Vinci procedure growth (%)+67FY2025+35Apr-Jun 2026Synektik annual report and interim report to June 2026
Halved in three quarters.

That dependence has been an engine. Dedicated reimbursement from April 2022 and new indications from August 202356 turned Polish da Vinci procedures from about 3 thousand a year into 19,8 thousand78. The same lever can stop. Polish procedure growth has slowed from 67% for the year to September 20259 to 35% in the April-June 2026 quarter10.

A pause in new indications, a tighter NFZ budget, or a change in VAT on medical equipment, which the company names as a risk11, would reach revenue within quarters.

Public investment money is a second lever. Management names equipment investment by the public health sector, funded from the European Union's 2021-2027 budget and the National Recovery Plan, as a main driver of sales12, and the oncology equipment tenders behind the 43% rise in equipment sales in the half-year to March 2026 were financed by the National Recovery Plan13. Those funds are temporary by design.

Polish procedure growth falling toward single digits without a new reimbursed indication would say the public engine has done its work.

The number that tests this threat
Reported
Polish da Vinci procedure growth, latest quarter
+35% in Apr-Jun 2026 (+67% in FY2025)

The public-funded demand; slowing without new indications.

Source: Synektik interim report, nine months to June 2026 ↗
References
  1. ReportedPublic procurement produced 85,5% of group revenue in the year to September 2025.
    Synektik annual management board report for the fiscal year to 30 September 2025 - risk factors, customers and suppliers (Intuitive's share of revenue and purchases, public procurement, Affidea, seasonality). — October 2024 - September 2025 · publ. December 2025 · source ↗
  2. ReportedThe operations that use its robots are paid for by the NFZ, which spent about 300 million złoty on nearly 11 000 robotic cancer operations in 2024, and only on three cancers.
    Polityka Zdrowotna - NFZ spending on robotic cancer operations: 2 100 operations for 59 million złoty in 2022, 5 400 for 167 million złoty in 2023, about 300 million złoty on nearly 11 000 in 2024; only prostate, colorectal and uterine cancer reimbursed; average cost about 30 thousand złoty. — 2022-2024 · publ. 2025 · source ↗
  3. ReportedThe operations that use its robots are paid for by the NFZ, which spent about 300 million złoty on nearly 11 000 robotic cancer operations in 2024, and only on three cancers.
    Polityka Zdrowotna - NFZ spending on robotic cancer operations: 2 100 operations for 59 million złoty in 2022, 5 400 for 167 million złoty in 2023, about 300 million złoty on nearly 11 000 in 2024; only prostate, colorectal and uterine cancer reimbursed; average cost about 30 thousand złoty. — 2022-2024 · publ. 2025 · source ↗
  4. ReportedThe company lists the level of public health funding among the main factors affecting its results.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - income statement, segment note, cash flow and balance sheet. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  5. ReportedDedicated reimbursement from April 2022 and new indications from August 2023 turned Polish da Vinci procedures from about 3 thousand a year into 19,8 thousand.
    Synektik interim report for the fiscal year to 30 September 2022 - revenue, segments, installed base in Poland, Czechia and Slovakia, the first dedicated reimbursement and example tenders. — October 2021 - September 2022 · publ. November 2022 · source ↗
  6. ReportedDedicated reimbursement from April 2022 and new indications from August 2023 turned Polish da Vinci procedures from about 3 thousand a year into 19,8 thousand.
    Synektik quarterly report for the fourth quarter of the fiscal year to 30 September 2023 - revenue up 168%, order intake, recurring revenue, installed base and procedures. — October 2022 - September 2023 · publ. November 2023 · source ↗
  7. ReportedDedicated reimbursement from April 2022 and new indications from August 2023 turned Polish da Vinci procedures from about 3 thousand a year into 19,8 thousand.
    Synektik interim report for the fiscal year to 30 September 2022 - revenue, segments, installed base in Poland, Czechia and Slovakia, the first dedicated reimbursement and example tenders. — October 2021 - September 2022 · publ. November 2022 · source ↗
  8. ReportedDedicated reimbursement from April 2022 and new indications from August 2023 turned Polish da Vinci procedures from about 3 thousand a year into 19,8 thousand.
    Synektik annual management board report for the fiscal year to 30 September 2025 - operating review: da Vinci systems and procedures, orders, recurring revenue, radiopharmaceutical products and the Baltic expansion. — October 2024 - September 2025 · publ. December 2025 · source ↗
  9. ReportedPolish procedure growth has slowed from 67% for the year to September 2025 to 35% in the April-June 2026 quarter.
    Synektik annual management board report for the fiscal year to 30 September 2025 - operating review: da Vinci systems and procedures, orders, recurring revenue, radiopharmaceutical products and the Baltic expansion. — October 2024 - September 2025 · publ. December 2025 · source ↗
  10. ReportedPolish procedure growth has slowed from 67% for the year to September 2025 to 35% in the April-June 2026 quarter.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - management commentary: orders, backlog, da Vinci systems and procedures, recurring revenue, radiopharmaceutical sales and seasonality. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  11. ReportedA pause in new indications, a tighter NFZ budget, or a change in VAT on medical equipment, which the company names as a risk, would reach revenue within quarters.
    Synektik annual management board report for the fiscal year to 30 September 2025 - risk factors, customers and suppliers (Intuitive's share of revenue and purchases, public procurement, Affidea, seasonality). — October 2024 - September 2025 · publ. December 2025 · source ↗
  12. ReportedManagement names equipment investment by the public health sector, funded from the European Union's 2021-2027 budget and the National Recovery Plan, as a main driver of sales, and the oncology equipment tenders behind the 43% rise in equipment sales in the half-year to March 2026 were financed by the National Recovery Plan.
    Synektik annual management board report for the fiscal year to 30 September 2025 - risk factors, customers and suppliers (Intuitive's share of revenue and purchases, public procurement, Affidea, seasonality). — October 2024 - September 2025 · publ. December 2025 · source ↗
  13. ReportedManagement names equipment investment by the public health sector, funded from the European Union's 2021-2027 budget and the National Recovery Plan, as a main driver of sales, and the oncology equipment tenders behind the 43% rise in equipment sales in the half-year to March 2026 were financed by the National Recovery Plan.
    Synektik management board report for the half-year 1 October 2025 - 31 March 2026 - including the HistoSonics Edison exclusive distribution agreement and the installed base at March 2026. — October 2025 - March 2026 · publ. June 2026 · source ↗
Sources
Generated September 24, 2026